Transaction · 0001221590-26-000013

BIENAIME JEAN JACQUES

BIENAIME JEAN JACQUES, DIR, reported a transaction classified as grant at Keros Therapeutics, Inc. involving 7433.000000 shares for an estimated $0.00. Reported holdings after the transaction were 7433.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ADIR
KROSKeros Therapeutics, Inc.
Filing timeJun 05
Trade dateJun 03, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$10.30
Pre-filing
1mo ago +13.7%1w ago +9.8%1d ago +2.4%
Returns since
7d -1.5%30d +9.3%90d +10.8%180d +10.8%1y +10.8%

KROS price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
KROS since 2026-06-05Filed 91 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001221590-26-000013
Stock Option (right to buy)
Transaction date
Jun 03, 2026
Filed Jun 05, 2026, 08:15 PM · 2d delay
Shares
7.43k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
7.43k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Increase
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting…

  2. F2

    The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of…

Original filing · 0001221590-26-000013
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

KROS